Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma-Reference-Cited by-同舟云学术

Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma

Published:2012-11 Issue:5 Volume:152 Page:851-862
ISSN:0039-6060
Container-title:Surgery
language:en
Short-container-title:Surgery

Author:

Lee Jae-Lyun,Kim Song Cheol,Kim Ji-Hoon,Lee Sang Soo,Kim Tae-Won,Park Do Hyun,Seo Dong Wan,Lee Sung Koo,Kim Myung-Hwan,Kim Jong Hoon,Park Jin-Hong,Shin Sang Hyun,Han Duck Jong

Publisher

Elsevier BV

Subject

Surgery

Reference45 articles.

1. 139 KCCR-affiliated hospitals. 2002 annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals;Shin;Cancer Res Treat,2004

2. Global cancer statistics, 2002;Parkin;CA Cancer J Clin,2005

3. Current therapies and advances in the treatment of pancreatic cancer;Mancuso;Crit Rev Oncol Hematol,2006

4. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer;Heinemann;J Clin Oncol,2006

5. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial;Louvet;J Clin Oncol,2005

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Executive Summary of the American Radium Society Appropriate Use Criteria for Neoadjuvant Therapy for Nonmetastatic Pancreatic Adenocarcinoma;American Journal of Clinical Oncology;2023-12-22

2. The oscillatory behavior and determination of the half-life of Dendrobium candidum;Biophysical Society of GuangDong Province Academic Forum: Precise Photons and Life Health (PPLH 2022);2023-04-04

3. CDCA8/SNAI2 Complex Activates CD44 to Promote Proliferation and Invasion of Pancreatic Ductal Adenocarcinoma;Cancers;2022-11-04

4. Defining the Optimal Duration of Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma;Pancreas;2022-10

5. Radiation therapy in borderline resectable pancreatic cancer: A review;Surgery;2022-07